2025 · 2nd Quarter (Apr 1 - June 30)

AMGEN, INC.

Filed by WILLIAMS AND JENSEN, PLLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 18, 2025
Income: $60,000.00
Expenses: Not reported
Registrant: WILLIAMS AND JENSEN, PLLC
Client: AMGEN, INC.
Filing UUID: aa296fa3-944d-4fe4-a776-51fb87bfd853
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

CPT · Copyright/Patent/Trademark

Issues related to patent protections.

HCR · Health Issues

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular health. Pharmacy benefit manager reform proposals.

MMM · Medicare/Medicaid

General education about policies impacting pharmaceutical development, approval, reimbursement, Medicare Part D and Medicare Part B, and 340B policies. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act".

Literal federal measure citations: H.R. 1

TAX · Taxation/Internal Revenue Code

Tax issues related to the pharmaceutical industry. H.R. 1, "One Big Beautiful Bill Act".

Literal federal measure citations: H.R. 1

BUD · Budget/Appropriations

Policies impacting disease prevention.

LBR · Labor Issues/Antitrust/Workplace

Issues related to antitrust legislation.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.